Clinical trial shows Ketamine is effective for treatment-resistant depression
March 31, 2019
Clinical trial shows Ketamine is effective for treatment-resistant depression A recent clinical trial looked to identify optimal intravenous ketamine dose for the treatment of depression. This double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine compared low (0.1 mg/kg and 0.2 mg/kg) standard (0.5 mg/kg), and high…
Keep ReadingAlternative NMDA modulator fails but Ketamine is available to patients right now
March 17, 2019
Allergan Announces Phase 3 Results for Rapastinel as an Adjunctive Treatment of Major Depressive Disorder (MDD) -- Three acute pivotal studies did not meet their primary endpoint ---- Interim analysis of relapse prevention study suggests the primary endpoint will not be met - Allergan announces…
Keep ReadingKetamine is approved by FDA
March 17, 2019
Ketamine is approved by FDA A ketamine-like drug is the first new antidepressant to get FDA approval in years.
Keep ReadingDepression
February 10, 2019
Depression For people struggling with depression, treatment is crucial. Unfortunately, traditional treatments don’t work for everyone; about 30% of people with depression don’t respond to traditional pharmaceutical treatment, and even for people who do respond, antidepressants can take up to eight weeks to take effect…
Keep ReadingPTSD
February 10, 2019
PTSD When people hear “PTSD”, they generally think of veterans of the military. However, PTSD is a diagnosis that relates to someone who may have experienced or witnessed a traumatic event. PTSD is a debilitating anxiety disorder characterized by intrusive re-experiences of the traumatic events,…
Keep Reading